Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
11.41
+0.23 (2.06%)
Dec 20, 2024, 4:00 PM EST - Market closed
Evolent Health Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Evolent Health stock have an average target of 25.9, with a low estimate of 15 and a high estimate of 41. The average target predicts an increase of 126.99% from the current stock price of 11.41.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 22, 2024.
Analyst Ratings
The average analyst rating for Evolent Health stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $45 → $15 | Buy | Maintains | $45 → $15 | +31.46% | Nov 22, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $34 → $28 | Buy | Maintains | $34 → $28 | +145.40% | Nov 18, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $33 → $21 | Strong Buy | Maintains | $33 → $21 | +84.05% | Nov 13, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +75.28% | Nov 12, 2024 |
| Barclays | Barclays | Buy Maintains $39 → $19 | Buy | Maintains | $39 → $19 | +66.52% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
2.59B
from 1.96B
Increased by 31.68%
Revenue Next Year
2.96B
from 2.59B
Increased by 14.35%
EPS This Year
0.75
from -1.28
EPS Next Year
1.01
from 0.75
Increased by 34.87%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.7B | 3.2B | 3.8B | |||
| Avg | 2.6B | 3.0B | 3.4B | |||
| Low | 2.5B | 2.6B | 2.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 37.6% | 25.6% | 28.6% | |||
| Avg | 31.7% | 14.3% | 13.9% | |||
| Low | 27.2% | 2.4% | -5.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.91 | 1.56 | 1.84 | ||
| Avg | 0.75 | 1.01 | 1.28 | ||
| Low | 0.42 | -0.16 | 0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 109.8% | 82.7% | ||
| Avg | - | 34.9% | 27.3% | ||
| Low | - | - | -95.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.